10 Best Low Risk Stocks To Buy in 2025

4. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 115

Equity Beta: 0.46x

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company specializing in the discovery, development, and commercialization of medicines for diabetes, oncology, immunology, and neuroscience. Its key products include insulin therapies, GLP-1 receptor agonists for diabetes and obesity, cancer treatments, and drugs for autoimmune and neurological disorders. LLY operates in major global markets, distributing its medicines through healthcare providers, pharmacies, and hospitals. The company invests heavily in research and development to drive innovation in biologics, gene therapy, and next-generation treatments. Its strategy focuses on expanding its drug portfolio, advancing precision medicine, and addressing unmet medical needs.

Eli Lilly and Company (NYSE:LLY) has several significant pipeline catalysts anticipated for the remainder of the calendar year, including readouts from the orforglipron program, a small molecule oral GLP-1 nonpeptide agonist with studies in type 2 diabetes and obesity. The company will also receive the first readout from the retatrutide program, a triple-acting injectable incretin being studied in overweight patients with osteoarthritis of the knee, which could potentially offer a significant step change in weight loss outcomes for higher BMI patients who cannot reach their goals on medicines like tirzepatide. In oncology, 2025 is particularly important for the Jaypirca (pirtobrutinib) program, with at least two randomized studies reading out, including one against chemoimmunotherapy in newly diagnosed CLL patients and another head-to-head study against ibrutinib in CLL.

Eli Lilly and Company (NYSE:LLY) maintains a strong position with Verzenio in breast cancer, currently seeing about 15% of new patient starts going to their competitor in overlapping populations, while remaining the standard of care for the high-risk population. Looking ahead, LLY has identified three potential game-changing opportunities: EMBER-4 in breast cancer, Lp(a) in cardiac disease, and Alzheimer’s disease prevention, with the latter particularly significant as it involves preventing disease onset through early intervention with blood testing. With a strong portfolio of drugs under research and a low equity beta of 0.46x, LLY is one of the best low risk stocks to buy in 2025.